How to Conduct Clinical Trials in China for Foreign Pharma: 2026 Guide

Foreign pharmaceutical companies can now achieve Investigational New Drug (IND) approval in China in as few as 60 working days under the silent approval mechanism, a dramatic reduction from the 12–18 months required a decade ago. This guide provides a strategic roadmap for conducting clinical trials in China in 2026, covering regulatory pathways, operational models, and compliance requirements under the National Medical Products Administration (国家药品监督管理局, NMPA, Guójiā Yàopǐn Jiāndū Guǎnlǐ Jú) and its evolving legal framework. With China’s clinical trial market projected to reach $7.2 billion by 2026 and patient recruitment timelines 3–5 times faster than in the US or EU, the opportunity for foreign sponsors is immense — but so are the pitfalls around data sovereignty, site selection, and regulatory alignment.

The 2026 Regulatory Framework for Foreign Clinical Trials

China’s regulatory environment has undergone transformative change since the 2017 ICH membership and the 2020 Drug Administration Law. By 2026, foreign sponsors benefit from three landmark reforms: 60-day IND silent approval (no news is good news), the Global Multi-Regional Clinical Trial (MRCT) Harmonisation Programme under ICH E17 guidelines, and expanded acceptance of overseas clinical data for registration when trials meet NMPA’s standards for ethnicity sensitivity and data quality. The NMPA now processes over 3,500 IND applications annually, of which approximately 40% come from foreign-sponsored entities or their Chinese affiliates.

The key regulatory bodies include the NMPA’s Center for Drug Evaluation (CDE, 药品审评中心, Yàopǐn Shěnpíng Zhōngxīn), which handles IND reviews, and the National Health Commission (NHC, 国家卫生健康委员会, Guójiā Wèishēng Jiànkāng Wěiyuánhuì), which oversees clinical trial site accreditation. Foreign sponsors must also comply with the Personal Information Protection Law (PIPL, 个人信息保护法, Gèrén Xìnxī Bǎohù Fǎ), enacted in 2021, and the Data Security Law (DSL, 数据安全法, Shùjù Ānquán Fǎ), which impose strict requirements on cross-border data transfers of personal health information — including clinical trial patient data. By 2026, a dedicated Clinical Trial Data Export Review mechanism has been operational for two years, requiring sponsors to submit a Data Export Impact Assessment (DEIA) for any patient-level data leaving China.

The Drug Registration Regulation (药品注册管理办法, Yàopǐn Zhùcè Guǎnlǐ Bànfǎ), revised in 2020 and further clarified through 2024 circulars, remains the foundational document. Foreign sponsors must designate a China-based legal entity or a qualified agent to hold the IND and ultimately the New Drug Application (NDA). This entity can be a wholly foreign-owned enterprise (外商独资企业, WFOE, wàishāng dúzī qǐyè) specifically licensed for pharmaceutical R&D, or a contractual arrangement with a local partner through a clinical research organisation (CRO).

Three Clinical Trial Models for Foreign Pharma in 2026

Foreign sponsors have three primary pathways to conduct trials in China: Independent IND via WFOE, Multi-Regional Clinical Trial (MRCT) with China inclusion, and Overseas Data Bridging with confirmatory local trial. Each model carries distinct regulatory burden, timeline, and cost implications. The table below compares them across six critical dimensions.

Decision Framework: If your drug is a novel first-in-class therapy targeting a disease with high unmet need in China (e.g., certain oncology subtypes where China has distinct genetic prevalence), choose the Independent IND via WFOE pathway for maximum speed and data ownership. If your drug is already in global Phase II or III trials and you want China included for a simultaneous global launch, choose the MRCT with China inclusion pathway — but ensure your global protocol includes a China-specific ethnicity analysis plan and a qualified Chinese principal investigator from the start. If your drug is already approved in the US or EU with robust safety data and you seek a conditional approval in China with a post-marketing confirmatory trial, choose the Overseas Data Bridging plus confirmatory trial model, though be prepared for the longest timeline and highest upfront cost.

Pitfalls in Model Selection

The IND Application Process: Step-by-Step for Foreign Sponsors

The IND process in China follows a structured, largely digital workflow through the CDE’s online portal (药审中心网站, Yàoshěn Zhōngxīn Wǎngzhàn). Here is the step-by-step sequence as of 2026:

1. Pre-IND Meeting (Pre-IND沟通交流会议, Pre-IND Gōutōng Jiāoliú Huìyì): A voluntary but strongly recommended 90-minute video conference with CDE reviewers. Submit your briefing package 30–45 days before the requested meeting date. CDE will provide written feedback on trial design, endpoint selection, and ethnicity data requirements. Cost: RMB 50,000–80,000 for preparation and travel (if in-person requested).
2. Submission of IND Dossier: Submit via CDE’s e-submission system, including complete pharmacology, toxicology, clinical pharmacology, and clinical study protocol. English-language modules are accepted with Chinese summaries for Sections 1–5; full Chinese translation is required for Section 2 (clinical overview) and the clinical study protocol. Format: PDF with digital signatures from the legal person of the China entity.
3. 60-Day Silent Approval Clock: The clock starts the first working day after submission. CDE issues a “Notice of Acceptance” within 5 days, then reviews for 60 calendar days. If no “Suspension Notice” is issued by Day 60, the IND is deemed approved and the sponsor may commence ethics committee submissions. Approximately 65% of INDs pass the silent approval threshold.
4. Ethics Committee (EC, 伦理委员会, Lúnlǐ Wěiyuánhuì) Review: Submit to the EC of each participating hospital. Review cycles range from 15–45 days. The NMPA has mandated that ECs accept a unified digital submission format since 2024, but individual hospital ECs may request supplementary documents. Tip: Engage a site management organisation (SMO) to pre-clear EC requirements per site.
5. First Patient Enrolled (FPI): Typically occurs 2–4 months after IND approval, depending on site activation. The NMPA requires reporting of FPI within 15 days via the CDE portal.

Total timeline from pre-IND meeting to FPI averages 6–9 months for Independent IND and 3–6 months for MRCT. Accelerated pathways, such as the Breakthrough Therapy Designation (突破性治疗药物, Tūpòxìng Zhìliáo Yàowù), can compress IND-to-FPI to under 4 months for qualifying drugs targeting life-threatening diseases.

Data Compliance: PIPL, DSL, and Your Trial Data

Data compliance is arguably the most complex and highest-risk area for foreign sponsors in 2026. The Personal Information Protection Law (PIPL) classifies clinical trial patient data as “sensitive personal information” requiring explicit consent for collection and separate, specific consent for any cross-border transfer. The Data Security Law (DSL) requires companies to categorise their data into tiered protection levels and implement corresponding security measures. For clinical trials, patient-level data typically falls under Tier 2 or Tier 3 (higher sensitivity), triggering obligations for encryption, access logging, and annual security audits.

The Data Export Impact Assessment (DEIA, 数据出境安全评估, Shùjù Chūjìng Ānquán Pínggū) is a mandatory process for any transfer of personal health information out of mainland China. As of 2026, the Cybersecurity Administration of China (CAC, 国家互联网信息办公室, Guójiā Hùliánwǎng Xìnxī Bàngōngshì) processes DEIAs in 30–45 working days. Depending on the trial model, sponsors may need to demonstrate that equivalent data protection standards apply at the receiving entity outside China. This often requires a data processing agreement with the global parent company and, for high-risk transfers, the appointment of a China-based data protection officer (DPO, 数据保护官, Shùjù Bǎohù Guān) registered with the CAC.

Practical strategies include: (1) data localisation — storing all patient-level data on servers in mainland China and only exporting anonymised, aggregated results for global analysis; (2) pseudonymisation before export using NMPA-approved algorithms; and (3) parallel data flows where the Chinese entity retains a complete copy locally while the global entity accesses a limited, compliant copy. Foreign sponsors who underestimate these requirements face suspension of data exports, fines of up to RMB 50 million (approximately $7 million), or revocation of the IND.

Patient Recruitment and Site Selection: The China Advantage

China’s advantage in patient recruitment is well-documented: with 1.3 billion people and 1,400+ GCP-certified hospitals, sponsors can recruit the same number of patients in one-third to one-fifth the time required in the US or EU for common conditions. For rare diseases, the advantage is even starker — China’s absolute patient numbers often mean a rare disease trial can be completed entirely within one or two provinces. However, recruitment speed varies dramatically by therapeutic area. Oncology trials in tier 1 cities (Beijing, Shanghai, Guangzhou) recruit fastest, while neurology and metabolic disease trials benefit from tier 2 city sites where patients have less access to clinical trials and higher willingness to participate.

Site selection should prioritise hospitals with (a) NMPA GCP certification valid through 2027 or later, (b) a strong principal investigator with a track record of NMPA-submitted trials, (c) an active ethics committee with a sub-30-day review cycle, and (d) proximity to patient populations relevant to the indication. The China Clinical Trial Registry (ChiCTR, 中国临床试验注册中心, Zhōngguó Línchuáng Shìyàn Zhùcè Zhōngxīn) is a critical resource for identifying active sites and investigators. Foreign sponsors should also consider partnering with a Site Management Organisation (SMO, 临床研究协调员组织, Línchuáng Yánjiū Xiétiáo Yuán Zǔzhī) for feasibility assessments and patient recruitment.

NEXT STEPS

1. Evaluate your pipeline for China suitability: Not every drug is a good candidate for a China clinical trial. Use our China Drug Suitability Assessment tool to score your pipeline molecule across four criteria: regulatory pathway, patient population, data compliance burden, and commercial viability. Expect a 2-hour analysis session with our regulatory pharmacist.
2. Set up your China legal entity for pharma R&D: A WFOE with the correct business scope for “pharmaceutical R&D and clinical trial sponsorship” is the foundation. Read our step-by-step Pharma WFOE Setup Guide for 2026 to avoid the 60–90 day delays caused by incorrect business scope applications. Budget RMB 50,000–120,000 for incorporation and licensing.
3. Conduct a Pre-IND Readiness Review with a China-based CRO: Before you invest in full dossier preparation, commission a Pre-IND readiness review from a qualified CRO with recent NMPA experience. Request our IND Readiness Checklist and a 2-day on-site (or virtual) gap analysis. The cost of early corrections is a fraction of post-submission amendment fees.

— China Gateway 360 —
Remote China market entry support, built around execution.